Novavax Inc
Here’s whether Novavax Inc (NVAX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+1.14% over 10 days); RSI 47 — healthy momentum range; strong 1-year return of +24.2%. Concerns: below the 50-day MA (medium-term momentum negative); 3-month momentum negative (-11.9%); declining volume on rally — weak conviction (0.73x 30d avg). Currently 25.8% off its 52-week high. Score: +2/7.
NVAX is holding above its long-term 200-day MA ($8.43) but has slipped below the 50-day MA ($8.95), pointing to short-term weakness in an otherwise intact trend. An RSI of 47.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +24.2% compares to +22.9% for SPY (beat the market by 1.3%). The current 25.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.